Moderna (MRNA.US) stock rose over 15.0% during today's session after the vaccine maker posted upbeat quarterly results mainly thanks to high sales of its covid vaccine. Company also implemented a $3 billion share repurchase program and for now maintained its full-year outlook for $21 billion in sales, based on current agreements. However potential authorization of an omicron booster shot could push this number higher.
-
Adjusted EPS rose to $5.24 per share, well above market estimates of $4.55, however it is a 18% drop compared to the second quarter of 2021.
-
Revenue rose 9% to $4.7 billion compared to last year, beating analysts’ expectations of $4.1 billion. That included $4.53 billion from the Covid shot, Spikevax. The remainder came from grants and collaborations.
-
Analysts from research firm Third Bridge expect that "the U.S. booster market potentially could represent over $7 billion annually for the next several years even if ongoing booster shots only focus on the 50 years of age and older cohort and other higher-risk groups."
-
On the other hand, the company had to write down nearly $500 million for vaccine inventory that has expired or is expected to expire before it can be used.
-
"Despite the slowing economy and challenges in the biotech industry, Moderna is in a unique position: a platform to drive scale and speed in research of new medicines, a strong balance sheet with $18 billion of cash and an agile, mission-driven team of over 3,400 people and growing. We will continue to invest and grow as we have never been as optimistic about Moderna's future. Right now, we have four infectious disease vaccines in Phase 3 trials, and later this year, we expect important data from proof-of-concept studies in rare diseases and immuno-oncology," said Stephane Bancel, Chief Executive Officer of Moderna.
-
Analysts are cautiously optimistic about Moderna stock with a price target of $216.55 and Moderate Buy consensus rating based on five Buys, six Holds, and one Sell.
-
Moderna's sales may increase in the coming quarters, especially if the covid theme returns in the autumn. In addition, vaccines against other diseases may provide additional sources of revenue and a share buyback program improves investor sentiment. Nevertheless, much will depend on the amount of people who will be willing to take booster doses as covid vaccine sales are currently a key revenue component.
Moderna (MRNA.US) stock plunged around 30.0% since January 2022, however buyers launched a recovery move in mid-June. Today stock price rose sharply following upbeat quarterly figures and broke above long-term downward trendline. Currently the price is testing 200 SMA (red line). Should break higher occur, the next target for bulls lies around $206.00 and is marked with 23.6% Fibonacci retracement of the downward wave launched in August 2021. The nearest key support can be found around $115.80, where recent lows are located. Source: xStation5
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appThe content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
